RxSight, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Aziz Mottiwala
- Full Time Employees
- 461
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Columbia Aliso Viejo CA United States of America 92656
- IPO Date
- Jul 30, 2021
- CIK
- 0001111485
- Website
- rxsight.com
- Similar Companies
- Business
- RxSight, Inc. (Nasdaq: RXST) develops, manufactures and commercializes light adjustable intraocular lenses and related equipment for customized vision correction in cataract surgery patients; its proprietary RxSight system comprises the RxSight Light Adjustable Lens (LAL) and LAL+, photosensitive intraocular lenses that enable post-operative adjustments via ultraviolet light to optimize uncorrected visual acuity and correct low levels of astigmatism as low as 0.50 diopters; the RxSight Light Delivery Device (LDD), an office-based treatment console that delivers programmed UV light patterns to modify the LAL; and the RxSight Planner software for treatment planning. The company targets ophthalmologists and cataract surgeons serving premium intraocular lens (IOL) markets, primarily in the United States where it holds FDA approval and maintains an installed base exceeding 1,000 LDDs; it operates from headquarters in Aliso Viejo, California, founded in 1997 as Calhoun Vision, Inc. and renamed RxSight in February 2017. In recent developments, RxSight realigns its U.S. commercial organization by integrating clinical and sales teams to enhance LAL practice integration and launches new practice development programs leveraging insights from over 250,000 LAL cases; it enters international markets including South Korea and Singapore in 2025 while planning further expansion into Asia and Europe; preliminary 2024 results show full-year revenue of $139.9 million with 79% LAL procedure growth and issues 2025 revenue guidance of $185-$197 million alongside gross margin expansion to 71-73%.
Head-To-Head Comparison: RxSight (NASDAQ:RXST) and Futureworld (OTCMKTS:FWDG)
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight Q2 Earnings Call Highlights
RxSight Q2 Earnings Call Highlights
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook
RxSight: After Dropping To The Bottom, It's Time To Pick It Up
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement